UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

2020

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 000-50194

hmsy-20200331_g1.jpg
HMS HOLDINGS CORP.

(Exact name of registrant as specified in its charter)

Delaware11-3656261
Delaware11-3656261
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
5615 High Point Drive Irving, TX75038
Irving,TX
(Address of principal executive offices)(Zip Code)

(214) 453-3000

(Registrant’s telephone number, including area code)

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock $0.01 par valueHMSYThe Nasdaq Stock Market LLC
Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  ☒ Yes   No  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered
Common Stock $0.01 par valueHMSY

The Nasdaq Stock Market LLC

(Nasdaq Global Select Market)


As of May 2, 2019,4, 2020, there were approximately 87,095,92088,414,262 shares of the registrant’s common stock outstanding.




HMS HOLDINGS CORP. AND SUBSIDIARIES

QUARTERLY REPORT ON FORM 10-Q

FOR THE THREE MONTHS ENDED MARCH 31, 2019

INDEX

2020
TABLE OF CONTENTS
Page
Page
Glossary1
March 31, 20192020 (unaudited) and December 31, 20182019
Three Months Ended March 31, 20192020 and 20182019 (unaudited)
Three Months Ended March 31, 20192020 and 20182019 (unaudited)
Three Months Ended March 31, 20192020 and 20182019 (unaudited)
Three Months Ended March 31, 20192020 and 20182019 (unaudited)





Glossary

Throughout

Certain key terms used throughout this Quarterly Report on Form 10-Q the Company may use certain abbreviations, acronyms and terms whichin our other filings are described below:

ACA

ACAPatient Protections and Affordable Care Act, as amended by the Health Care and Education

Reconciliation Act

of 2010
ACOAccountable Care Organizationcare organization
ADRAdditional Documentation Requestdocumentation request
ASCAIArtificial intelligence
ASCAccounting Standards Codification
ASOAdministrative Service Onlyservice only
ASUAccounting Standards Update
CHIPCARES ActCoronavirus Aid, Relief, and Economic Security Act
CHIPChildren's Health Insurance Program
CMSCenters for Medicare & Medicaid Services
CMS NHECMS National Health Expenditures
COBCoordination of benefitsBenefits
COSOCommittee of Sponsoring Organizations of the Treadway Commission
Credit AgreementThe Amended and Restated Credit Agreement dated as of May 3, 2013, as amended by Amendment No. 1 to Amended and Restated Credit Agreement dated as of March 8, 2017, and as further amended by Amendment No. 2 to Amended and Restated Credit Agreement, dated as of December 19, 2017, by and among HMS Holdings Corp. the Guarantors party thereto, the Lenders party thereto and Citibank, N.A. as Administrative Agent
DSODays sales outstanding
ERISAEmployment Retirement Income Security Act of 1974
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
Form 10-QHMS Holdings Corp. Quarterly Report on Form 10-Q for the quarterly period ended March 31, 20192020
HIPAAHealth Insurance Portability and Accountability Act of 1996
HITECHHealth Information Technology for Economic and Clinical Health Act
IRCInternal Revenue Code
IRSU.S. Internal Revenue Service
LIBOR or LIBO RateIntercontinental Exchange London Interbank Offered Rate (or any successor rate determined in accordance with the Credit Agreement)
MCOManaged Care Organizationcare organization
PBMMLPharmacy Benefit ManagerMachine learning
PHINLPNatural language processing
PBMPharmacy benefit manager
PHIProtected health information
PIPHMPayment IntegrityPopulation Health Management
PMPMPIPer Member Per MonthPayment Integrity
1


PMPYPMPMPer Member Per Yearmember per month
R&D CreditPMPYU.S. Research and Experimentation Tax Credit pursuant to IRC Section 41Per member per year
RACRecovery Audit Contractor
RFPRequest for proposal
ROURight-of-use
SECRPARobotic process automation
SECU.S. Securities and Exchange Commission
Securities ActSecurities Act of 1933, as amended
Section 199 DeductionSG&AU.S. Production Activities Deduction pursuant to IRC Section 199
SG&ASelling, general and administrative
TPLThird-party liability
TPMTotal Population Management
U.S. GAAPUnited States Generally Accepted Accounting Principles
2006 Stock PlanVAHMS Holdings Corp. Fourth Amended and Restated 2006 Stock Plan, as amended by Amendment No. 1 to the HMS Holdings Corp. Fourth Amended and Restated 2006 Stock Plan dated asU.S. Department of February 16, 2017Veterans Affairs
2016 Omnibus PlanHMS Holdings Corp. 2016 Omnibus Incentive Plan
2017 Tax ActTax Cuts and Jobs Act of 2017
20182019 Form 10-KHMS Holdings Corp. Annual Report on Form 10-K for the year ended December 31, 20182019
2019 Omnibus PlanHMS Holdings Corp. 2019 Omnibus Incentive Plan
401(k) PlanHMS Holdings Corp. 401(k) Plan


2


For purposes of this Form 10-Q, the terms “HMS,” “Company,” “we,” “us,” and “our” refer to HMS Holdings Corp. and its consolidated subsidiaries unless the context clearly indicates otherwise.

Cautionary Note Regarding Forward-Looking Statements

Included in this Form 10-Q are “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. From time to time, we also provide forward-looking statements in other materials we release to the public, as well as oral forward-looking statements. Such statements relate to our current expectations, projections and assumptions about our business, the economy and future events or conditions. They do not relate strictly to historical or current facts.

We have tried to identify forward-looking statements by using words such as “aim,” “anticipate,” "assume," “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “likely,” “may,” “outlook,” “plan,” “potential,” “project,” “seek,” “strategy,” “target,” “trend,” “will,” “would,” “could,” “should,” and variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. These statements include, among other things, the potential impacts of the novel coronavirus (COVID-19), information concerning our future growth, business strategy, strategic or operational initiatives, our future operating or financial performance, our ability to invest in and utilize our data and analytics capabilities to expand our solutions and services,offerings, the benefits and synergies to be obtained from completed and future acquisitions, the future performance of companies we have acquired,investments and strategic relationships, including VitreosHealth, Inc. ("VitreosHealth"), MedAdvisor Limited ("MedAdvisor") and West Claims Recovery Services, LLC ("Accent"), our future expenses, interest rates and tax rates, our ability to meet our future liquidity requirements, the impact of changes to U.S. healthcare legislation or healthcare spending affecting Medicare, Medicaid or other publicly funded or subsidized health programs, and other statements regarding our possible future actions, business plans, objectives and prospects.

Forward-looking statements are not guarantees and involve risks, uncertainties and assumptions that are difficult to predict. Actual results may differ materially from past results and from those indicated by such forward-looking statements if known or unknown risks or uncertainties materialize, or if underlying assumptions prove inaccurate. These risks and uncertainties include, among other things:

our ability to execute our business plans or growth strategy;
our ability to innovate, develop or implement new or enhanced solutions or services;
the nature of investment and acquisition opportunities we are pursuing, and the successful execution of such investments and acquisitions;
our ability to successfully integrate acquired businesses and realize synergies;
significant competition for our solutions and services;
variations in our results of operations;
our ability to accurately forecast the revenue under our contracts and solutions;
our ability to protect our systems from damage, interruption or breach, and to maintain effective information and technology systems and networks;
our ability to protect our intellectual property rights, proprietary technology, information processes and know-how;
our failure to maintain a high level of customer retention or the unexpected reduction in scope or termination of key contracts with major customers;
customer dissatisfaction or our non-compliance with contractual provisions or regulatory requirements;
our failure to meet performance standards triggering significant costs or liabilities under our contracts;
our inability to manage our relationships with data sources and suppliers;
our reliance on subcontractors and other third party providers and parties to perform services;
our ability to continue to secure contracts and favorable contract terms through the competitive bidding process;
pending or threatened litigation;
unfavorable outcomes in legal proceedings;
our success in attracting and retaining qualified employees and members of our management team;
our ability to generate sufficient cash to cover our interest and principal payments under our credit facility;
unexpected changes in tax laws, regulations or guidance and unexpected changes in our effective tax rate;
unanticipated increases in the number or amount of claims for which we are self-insured;
accounting changes or revisions;
changes in the U.S. healthcare environment or healthcare financing system, including regulatory, budgetary or political actions that affect healthcare spending or the practices and operations of healthcare organizations;
our failure to comply with applicable laws and regulations governing individual privacy and information security or to protect such information from theft and misuse;
our ability to comply with current and future legal and regulatory requirements;
negative results of government or customer reviews, audits or investigations;
state or federal limitations related to outsourcing of certain government programs or functions;
restrictions on bidding or performing certain work due to perceived conflicts of interests;
the market price of our common stock and lack of dividend payments; and
anti-takeover provisions in our corporate governance documents.

the course of the COVID-19 pandemic and the responses to the pandemic, and their effects on our business and operations, including those of our customers and partners, and general economic, business and market conditions;

our ability to execute our business plans or growth strategy;
our ability to innovate, develop or implement new or enhanced solutions or services;
the nature of acquisition, investment, strategic relationship and divestiture opportunities we are pursuing, and our ability to successfully execute on such opportunities;
our ability to successfully integrate acquired businesses and operations and realize synergies;
significant and increased competition related to our solutions and services;
variations in our results of operations;
our ability to accurately forecast the revenue under our contracts and solutions;
our ability to protect our systems from damage, interruption or breach, and to maintain effective information and technology systems and networks, including during a catastrophic or extraordinary event, such as COVID-19;
3


our ability to protect our intellectual property rights, proprietary technology, information processes and know-how;
our failure to maintain a high level of customer retention or the unexpected reduction in scope or termination of key contracts with major customers;
customer dissatisfaction or our non-compliance with contractual provisions or regulatory requirements;
our failure to meet performance standards triggering significant costs or liabilities under our contracts;
our inability to manage our relationships with data sources and suppliers;
our reliance on subcontractors and other third party providers and parties to perform services;
our ability to secure future contracts and favorable contract terms through the competitive bidding process;
pending or threatened litigation;
unfavorable outcomes in legal proceedings;
our success in attracting and retaining qualified employees and members of our management team;
our ability to generate sufficient cash to cover our interest and principal payments under our credit facility;
changes in tax laws, regulations or guidance and unexpected changes in our effective tax rate;
unanticipated increases in the number or amount of claims for which we are self-insured;
accounting changes or revisions;
risks relating to our international operations, including political, regulatory, economic, foreign exchange, tax compliance and other risks;
changes in the healthcare environment or healthcare financing system, including regulatory, budgetary or political actions that affect healthcare spending or the practices and operations of healthcare organizations;
our failure to comply with applicable laws and regulations governing individual privacy and information security, domestically and internationally, or to protect such information from theft and misuse;
our ability to comply with current and future legal and regulatory requirements;
negative results of government or customer reviews, audits or investigations;
state or federal limitations related to outsourcing of certain government programs or functions;
restrictions on bidding or performing certain work due to perceived conflicts of interests;
the market price of our common stock and lack of dividend payments; and
anti-takeover provisions in our corporate governance documents.
These and other risks are discussed in this Form 10-Q and under the headings “Business,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Quantitative and Qualitative Disclosures About Market Risk” of our 20182019 Form 10-K, and in other documents we file with the SEC.

4


Any forward-looking statements made by us in this Form 10-Q speak only as of the date on which they are made. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. We caution readers not to place undue reliance upon any of these forward-looking statements. You are advised, however, to consult any further disclosures we make on related subjects in our reports and other filings with the SEC.

Market and Industry Data

This Form 10-Q may include market, industry and government data and forecasts that have been obtained from publicly available information, various industry publications, other published industry sources and our own internal data and estimates. We have not independently verified information from third-party informationsources and cannot make any representation as to the accuracy or completeness of such information. None of the reports and other materials of third-party sources referred to in this Form 10-Q were prepared for use in, or in connection with, this Form 10-Q.

Additionally, our internal data and estimates are based upon information obtained from our customers, our partners, trade and business organizations, publicly available information and other contacts in the markets in which we operate and our management’s understanding of industry conditions. Estimates are difficult to develop and inherently uncertain, and we cannot assure you that they are accurate. Our estimates involve risks and uncertainties and are subject to change based on various factors, including those detailed above and under “Part II, Item 1A. Risk Factors” of this Form 10-Q.

Trademarks and Trade Names

We have a number of registered trademarks, including HMS®, as well as the corresponding HMS + logo design mark, HMS IntegritySourceElli®, Eliza®, EssetteEssette®, and ElliVitreosHealth®and Accent®. These and other trademarks of ours appearing in this Form 10-Q are our property. Solely for convenience, trademarks and trade names of ours referred to in this Form 10-Q may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks and trade names. Other trademarks and trade names appearing in this Form 10-Q are the property of their respective owners. We do not intend our use or display of other companies' trademarks or trade names to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.


5



PART I — FINANCIAL INFORMATION


Item 1. Financial Statements

HMS HOLDINGS CORP. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

  March 31,
2019
 

December 31,

2018

Assets (unaudited)  
Current assets:        
Cash and cash equivalents $219,857  $178,946 
Accounts receivable, net of allowance of $14,037 and $13,683, at March 31, 2019 and December 31, 2018, respectively  204,795   206,772 
Prepaid expenses  22,097   19,970 
Income tax receivable  17,628   18,817 
Deferred financing costs, net  564   564 
Other current assets  249   240 
Total current assets  465,190   425,309 
Property and equipment, net  90,294   94,435 
Goodwill  487,617   487,617 
Intangible assets, net  64,801   67,140 
Operating lease right-of-use assets  20,110   - 
Deferred financing costs, net  1,532   1,673 
Other assets  3,110   2,344 
Total assets $1,132,654  $1,078,518 
         
Liabilities and Shareholders' Equity        
Current liabilities:        
Accounts payable, accrued expenses and other liabilities $63,078  $74,902 
Estimated liability for appeals  24,043   21,723 
Total current liabilities  87,121   96,625 
Long-term liabilities:        
Revolving credit facility  240,000   240,000 
Operating lease liabilities  18,677   - 
Net deferred tax liabilities  19,710   18,485 
Other liabilities  6,758   10,012 
Total long-term liabilities  285,145   268,497 
Total liabilities  372,266   365,122 
Commitments and contingencies        
Shareholders' equity:        
Preferred stock -- $0.01 par value; 5,000,000 shares authorized; none issued      
Common stock -- $0.01 par value; 175,000,000 shares authorized; 100,745,077 shares issued and 87,081,712 shares outstanding at March 31, 2019; 98,924,501 shares issued and 85,261,664 shares outstanding at December 31, 2018;  1,007   989 
Capital in excess of par value  453,080   425,748 
Retained earnings  441,877   422,235 
Treasury stock, at cost: 13,663,194 shares at March 31, 2019 and 13,663,194 shares at December 31, 2018  (135,576)  (135,576)
Total shareholders' equity  760,388   713,396 
Total liabilities and shareholders' equity $1,132,654  $1,078,518 

March 31,
2020
December 31,
2019
Assets(unaudited)
Current assets:
Cash and cash equivalents$148,033  $139,268  
Accounts receivable, net234,901  223,443  
Prepaid expenses and other current assets22,231  30,925  
Income tax receivable524  3,210  
Deferred financing costs, net564  564  
Total current assets406,253  397,410  
Property and equipment, net86,764  86,947  
Goodwill597,803  599,351  
Intangible assets, net128,170  131,849  
Operating lease right-of-use assets16,544  17,493  
Deferred financing costs, net968  1,109  
Other assets14,586  10,117  
Total assets$1,251,088  $1,244,276  
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable, accrued expenses and other liabilities$81,242  $97,747  
Liability for appeals3,906  3,570  
Total current liabilities85,148  101,317  
Long-term liabilities:
Revolving credit facility240,000  240,000  
Operating lease liabilities13,839  14,881  
Net deferred tax liabilities26,527  25,587  
Other liabilities7,727  7,626  
Total long-term liabilities288,093  288,094  
Total liabilities373,241  389,411  
Commitments and contingencies
Shareholders' equity:
Preferred stock -- $0.01 par value; 5,000,000 shares authorized; 0ne issued—  —  
Common stock -- $0.01 par value; 175,000,000 shares authorized;102,073,527 shares issued and 88,410,333 shares outstanding at March 31, 2020; 101,766,468 shares issued and 88,103,566 shares outstanding at December 31, 20191,021  1,018  
Capital in excess of par value490,261  479,964  
Retained earnings522,141  509,459  
Treasury stock, at cost: 13,663,194 shares at March 31, 2020 and December 31, 2019(135,576) (135,576) 
Total shareholders' equity877,847  854,865  
Total liabilities and shareholders' equity$1,251,088  $1,244,276  
See accompanying Notes to the unaudited Consolidated Financial Statements.


7



HMS HOLDINGS CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share amounts)

(unaudited)

  Three Months Ended
March 31, 
   2019   2018 
Revenue $147,953  $141,425 
Cost of services:        
Compensation  57,452   56,079 
Direct project and other operating expenses  20,199   16,648 
Information technology  13,105   12,263 
Occupancy  4,079   4,383 
Amortization of acquisition related software and intangible assets  4,166   8,132 
Total cost of services  99,001   97,505 
Selling, general and administrative expenses  29,246   31,998 
Total operating expenses  128,247   129,503 
Operating income  19,706   11,922 
Interest expense  (2,849)  (2,648)
Interest income  1,114   120 
Income before income taxes  17,971   9,394 
Income taxes  (1,671)  3,003 
Net Income $19,642  $6,391 
         
Basic income per common share:        
Net income per common share -- basic $0.23  $0.08 
Diluted income per common share:        
Net income per common share -- diluted $0.22  $0.07 
Weighted average shares:        
Basic  85,853   83,933 
Diluted  88,614   85,682 

Three Months Ended
March 31,
20202019
Revenue$171,412  $147,953  
Cost of services:
Compensation67,455  57,452  
Direct project and other operating expenses24,895  20,199  
Information technology14,903  13,105  
Occupancy4,362  4,079  
Amortization of acquisition related software and intangible assets5,505  4,166  
Total cost of services117,120  99,001  
Selling, general and administrative expenses35,839  29,246  
Total operating expenses152,959  128,247  
Operating income18,453  19,706  
Interest expense(2,262) (2,849) 
Interest income234  1,114  
Other income652  —  
Income before income taxes17,077  17,971  
Income taxes4,395  (1,671) 
Net income$12,682  $19,642  
Basic income per common share:
Net income per common share -- basic$0.14  $0.23  
Diluted income per common share:
Net income per common share -- diluted$0.14  $0.22  
Weighted average shares:
Basic88,202  85,853  
Diluted89,601  88,614  
See accompanying Notes to the unaudited Consolidated Financial Statements.


8



HMS HOLDINGS CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF

SHAREHOLDERS’ EQUITY (in

(in thousands, except share amounts)

amounts)

(unaudited)

  Three months ended March 31,
   2019   2018 
Common Stock and paid-in capital        
Balance, beginning of period $426,737  $369,686 
Exercise of stock options  23,139   144 
Stock-based compensation expense  10,979   9,494 
Vesting of restricted stock units, net of shares withheld for employee tax  (6,768)  (2,587)
Balance, end of period  454,087   376,737 
         
Retained earnings        
Balance, beginning of period  422,235   366,164 
Net income  19,642   6,391 
Cumulative effect of accounting changes  -   1,427 
Balance, end of period  441,877   373,982 
         
Treasury stock        
Balance, beginning of period  (135,576)  (129,621)
Purchase of treasury stock  -   (5,955)
Balance, end of period  (135,576)  (135,576)
         
Total shareholders' equity $760,388   615,143 
         
Shares outstanding        
Balance, beginning of period  98,924,501   96,536,251 
Exercise of stock options  1,443,685   9,043 
Vesting of restricted stock units, net of shares withheld for employee tax  376,891   330,860 
Balance, end of period  100,745,077   96,876,154 
         
Treasury Stock Outstanding        
Balance, beginning of period  13,663,194   13,279,393 
Purchase of treasury stock  -   383,801 
Balance, end of period  13,663,194   13,663,194 

Three Months Ended
March 31,
20202019
Common Stock and paid-in capital
Balance, beginning of period$480,982  $426,737  
Exercise of stock options125  23,139  
Stock-based compensation expense13,510  10,979  
Vesting of restricted stock units, net of shares withheld for employee tax(3,335) (6,768) 
Balance, end of period491,282  454,087  
Retained earnings
Balance, beginning of period509,459  422,235  
Net income12,682  19,642  
Balance, end of period522,141  441,877  
Treasury stock
Balance, beginning of period(135,576) (135,576) 
Purchase of treasury stock—  —  
Balance, end of period(135,576) (135,576) 
Total shareholders' equity$877,847  $760,388  
Shares issued
Balance, beginning of period101,766,468  98,924,501  
Exercise of stock options13,561  1,443,685  
Vesting of restricted stock units, net of shares withheld for employee tax293,498  376,891  
Balance, end of period102,073,527  100,745,077  
Treasury Stock
Balance, beginning of period13,663,194  13,663,194  
Purchase of treasury stock—  —  
Balance, end of period13,663,194  13,663,194  
See accompanying Notes to the unaudited Consolidated Financial Statements.


9



HMS HOLDINGS CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 Three Months Ended
March 31,
Three Months Ended
March 31,
  2019   2018 20202019
Operating activities:    Operating activities:
Net income $19,642  $6,391 Net income$12,682  $19,642  
Adjustments to reconcile net income to net cash provided by operating activities:        Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of property, equipment and software  7,930   7,345 Depreciation and amortization of property, equipment and software8,024  7,930  
Amortization of intangible assets  2,339   6,121 Amortization of intangible assets3,679  2,339  
Amortization of deferred financing costs  141   141 Amortization of deferred financing costs141  141  
Stock-based compensation expense  10,979   9,494 Stock-based compensation expense13,510  10,979  
Deferred income taxes  1,225   (777)Deferred income taxes940  1,225  
Noncash lease expense 1,196   - Noncash lease expense949  1,196  
Loss on disposal of assets  -   72 
Release of estimated liability for appeals  -   (8,436)
Changes in operating assets and liabilities:        Changes in operating assets and liabilities:
Accounts receivable  1,977   2,328 Accounts receivable(9,910) 1,977  
Prepaid expenses  (2,127)  2,539 
Other current assets  (9)  469 
Prepaid expenses and other current assetsPrepaid expenses and other current assets8,694  (2,136) 
Other assets  (766)  (25)Other assets(4,469) (766) 
Income taxes receivable  1,189   2,919 Income taxes receivable2,686  1,189  
Accounts payable, accrued expenses and other liabilities  (15,995)  (14,115)Accounts payable, accrued expenses and other liabilities(19,126) (15,995) 
Operating lease liabilities  (1,519  - Operating lease liabilities(1,042) (1,519) 
Estimated liability for appeals  2,320   271 
Liability for appealsLiability for appeals336  2,320  
Net cash provided by operating activities  28,522   14,737 Net cash provided by operating activities17,094  28,522  
Investing activities:        Investing activities:
Purchases of property and equipment  (369)  (791)Purchases of property and equipment(1,678) (369) 
Investment in capitalized software  (3,621)  (4,963)Investment in capitalized software(3,339) (3,621) 
Net cash used in investing activities  (3,990)  (5,754)Net cash used in investing activities(5,017) (3,990) 
Financing activities:        Financing activities:
Proceeds from exercise of stock options  23,139   144 Proceeds from exercise of stock options125  23,139  
Payments of tax withholdings on behalf of employees for net-share settlements  (6,768)  (2,587)Payments of tax withholdings on behalf of employees for net-share settlements(3,335) (6,768) 
Payments on capital lease obligations  8   - Payments on capital lease obligations(102)  
Purchases of treasury stock  -   (5,955)
Net cash provided by/(used in) financing activities  16,379   (8,398)
Net cash (used in)/provided by financing activitiesNet cash (used in)/provided by financing activities(3,312) 16,379  
Net increase in cash and cash equivalents  40,911   585 Net increase in cash and cash equivalents8,765  40,911  
Cash and Cash Equivalents        Cash and Cash Equivalents
Cash and cash equivalents at beginning of year  178,946   83,313 Cash and cash equivalents at beginning of year139,268  178,946  
Cash and cash equivalents at end of period $219,857  $83,898 Cash and cash equivalents at end of period$148,033  $219,857  
        
Supplemental disclosure of cash flow information:        Supplemental disclosure of cash flow information:
Cash paid for income taxes/(refunds received), net of refunds $(4,288) $626 Cash paid for income taxes/(refunds received), net of refunds$585  $(4,288) 
Cash paid for interest $2,771  $2,055 Cash paid for interest$2,134  $2,771  
        
Supplemental disclosure of non-cash activities:        Supplemental disclosure of non-cash activities:
Change in balance of accrued property and equipment purchases $(201) $881 Change in balance of accrued property and equipment purchases$(2,824) $(201) 

See accompanying Notes to the unaudited Consolidated Financial Statements.


11



HMS HOLDINGS CORP. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 20192020 and 2018

2019

(unaudited)

1.Business and Summary of Significant Accounting Policies

1.  Business and Summary of Significant Accounting Policies
(a) Business

The terms “HMS,” “Company,” “we,” “us,���us,” and “our” refer to HMS Holdings Corp. and its consolidated subsidiaries unless the context clearly indicates otherwise. HMS is an industry-leading provider of cost containment and analytical solutions in the healthcare marketplace. Our mission is to make healthcare work better for everyone. We use healthcare data, technology analytics and engagement solutions,analytics to deliver coordination of benefits, payment integrity,accuracy and population risk analytics, and carehealth management and consumer engagement solutions tothat help payershealthcare organizations reduce costs, improve healthcarehealth outcomes and enhance memberconsumer experiences. We provide coordination of benefits services to government and commercial healthcare payers to ensure that the correct party pays the claim. Our payment integrity services promote accuracy by fighting fraud, waste and abuse, and our total population management solutions provide risk-bearing organizations with reliable intelligence across their member populations to identify risks and improve patient engagement and outcomes. Together these various services help move the healthcare system forward for our customers. We currently operate as one1 business segment with a single management team that reports to the Chief Executive Officer.

The Consolidated Financial Statements and accompanying Notes in this Form 10-Q are unaudited. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. The results reported in these unaudited Consolidated Financial Statements are not necessarily indicative of the results that may be expected for any subsequent interim period or the entire year. These unaudited Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (“2019 Form 10-K”). The consolidated balance sheet as of December 31, 2019 included herein was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.
The preparation of the Company’s unaudited Consolidated Financial Statements requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the unaudited Consolidated Financial Statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. These statements include all adjustments (which include only normal recurring adjustments, except as disclosed) that management considers necessary to present a fair statement of the Company’s results of operations, financial position and cash flows. The results reported in these unaudited Consolidated Financial Statements should not be regarded as necessarily indicative of results that may be expected for the entire year. It is suggested that these unaudited Consolidated Financial Statements be read in conjunction with the Company’s consolidated financial statements and notes thereto as of and for the year ended December 31, 2018, which were filed with the SEC as part of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (“2018 Form 10-K”). The consolidated balance sheet as of December 31, 2018 included herein was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.

The preparation of the Company’s unaudited Consolidated Financial Statements requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, primarily accounts receivable, intangible assets, fixed assets, accrued expenses, estimated liability for appeals, the disclosure of contingent liabilities at the date of the unaudited Consolidated Financial Statements and the reported amounts of revenue and expenses during the reportingsuch interim periods. The Company’s actual results could differ from those estimates.

These unaudited Consolidated Financial Statements include HMS accounts and transactions and those of the Company’s wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

(b) Summary of Significant Accounting Policies

There have been no material changes to the Company’s significant accounting policies that are referenced in the 20182019 Form 10-K other than as described below with respect to leases.

10-K.



12


Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires most lessees to recognize a majority of the company’s leases on the balance sheet, which increases reported assets and liabilities. ASU 2016-02 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018 including interim periods within such annual reporting periods with early adoption permitted. The Company adopted this guidance on January 1, 2019, utilizing the optional transition method approach with an effective date of January 1, 2019. Consequently, financial information prior to the effective date was not updated and the disclosures required under the new standard are not provided for dates and periods prior to the effective date. There were no cumulative effect adjustments to retained earnings as part of adoption. The Company elected the available practical expedients, including the practical expedient to not separate lease and non-lease components of its leases and the short-term lease practical expedient. The Company’s internal control framework did not materially change, but existing internal controls were modified due to certain changes to business processes and systems to support the new leasing standard as necessary. The standard had a material impact on our consolidated balance sheets, the most significant impact being the recognition of approximately $21.3 million of ROU assets and $26.3 million lease liabilities on the effective date, but did not have an impact on our consolidated income statements. The Company continues to expect the impact of the adoption of the new standard to be immaterial to its net income and its internal control framework on an ongoing basis.


In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718) – Improvements to Nonemployee Share-Based Payment Accounting, (“ASU 2018-07”). ASU 2018-07 requires entities to apply similar accounting for share-based payment transactions with non-employees as with share-based payment transactions with employees. ASU 2018-07 is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2019. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses(“ (“ASU 2016-13”). ASU 2016-13 introduces the current expected credit losses methodology for estimating allowances for credit losses. ASU 2016-13 applies to all financial instruments carried at amortized cost and off-balance-sheet credit exposures not accounted for as insurance, including loan commitments, standby letters of credit, and financial guarantees. The new accounting standard does not apply to trading assets, loans held for sale, financial assets for which the fair value option has been elected, or loans and receivables between entities under common control. ASU 2016-13 is effective for public entities for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2020. When developing an estimate of the Company's expected credit losses, the Company considers all relevant information regarding the collectability of cash flows including historical information, customers' credit history and current financial conditions, industry trends and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15"). The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal use software. ASU 2018-15 is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted this guidance on January 1, 2020. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements ("ASU 2018-13"). The objective of the ASU is to improve the disclosures related to fair value measurement by removing, modifying, or adding disclosure requirements related to recurring and non-recurring fair value measurements. ASU 2018-13 is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted this guidance on January 1, 2020. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). The guidance eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences related to changes in ownership of equity method investments and foreign subsidiaries. The guidance also simplifies aspects of accounting for franchise taxes and enacted changes in tax laws or rates, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact on the Company’spermitted, including adoption in any interim period for which financial statements of adopting this guidance but thishave not
13


been issued. This guidance is not expected to have a material impact on the Company’s financial position, results of operations or internal control framework.

2.Revenue Recognition


2.  Revenue Recognition
The Company’s revenue disaggregated by solution for the three months ended March 31, 20192020 and 20182019 was as follows (in thousands):

 Three Months EndedThree Months Ended
March 31,
  March 31, 2019   March 31, 2018 20202019
Coordination of Benefits $105,851  $91,752 Coordination of Benefits$118,056  $105,851  
Payment Integrity  27,726   38,641 Payment Integrity39,308  27,726  
Total Population Management  14,376   11,032 
Population Health ManagementPopulation Health Management14,048  14,376  
Total $147,953  $141,425 Total$171,412  $147,953  

Coordination of benefits revenue is derived from contracts with state governments, and Medicaid managed care plans, and commercial entities that can span years with the option to renew. Types of service contracts could include: (a) the identification of erroneously paid claims; (b) the delivery of verified commercial insurance coverage information; (c) the identification of paid claims where another third party is liable; and (d) the identification and enrollment of Medicaid members who have access to employer insurance. Most of these types of service contracts contain multiple promises, all of which are not distinct within the context of the contract. Therefore, the promises represent a single, distinct performance obligation for the types of services we offer. Revenue derived from these performance obligations is largely based on variable consideration where, based on the number of claims or amount of findings the Company identified, a contingent or fixed transaction price/recovery percentage is allocated to each distinct performance obligation. The Company utilizes the expected value method to estimate the variable consideration related to the transaction price for its service contracts. Key inputs and assumptions in determining variable consideration include identified pricing and expected recoveries and/or savings. The expected recoveries and/or savings are based on historical experience of information received from our customers. Revenue is primarily recognized at a point in time when our customers realize economic benefits from our services when our services are completed. However, we have a limited number of fixed fee arrangements where revenue is recognized over time as performance obligations are satisfied within one to three years. Generally, coordination of benefit contract payment terms are not standardized within the respective contract; however, payment is typically due on demand and there is a clear and distinct history of customers making consistent payments.


Analytical services revenue consists of revenue for our payment integrity services and total population management solutions.

Payment integrity services revenue is derived from contracts with federal and state governments, commercial health plans and other at-risk entities that can span years with the option to renew. Types of service contracts could include: (a) services designed to ensure that healthcare payments are accurate and appropriate; and (b) the identification of over/under payments or inaccurate charges based on a review of medical records. Most of these types of service contracts contain multiple promises, all of which are not distinct within the context of the contract. Therefore, the promises represent a single, distinct performance obligation for the types of services we offer. Revenue derived from these performance obligations is largely based on variable consideration where, based on the amount of recovery findings the Company identifies, a contingent or fixed transaction price/recovery percentage is allocated to each distinct

14


performance obligation. The Company utilizes the expected value method to estimate the variable consideration related to the transaction price for its service contracts. Key inputs and assumptions in determining variable consideration include identified pricing and expected recoveries and/or savings. The expected recoveries and/or savings are based on historical experience of information received from our customers. Revenue is primarily recognized at a point in time when our customers realize economic benefits from our services when our services are completed. However, we have a limited number of fixed fee arrangements where revenue is recognized over time as performance obligations are satisfied within one to three years. Generally, payment integrity contract payment terms are not standardized within the respective contract; however, invoice payment is typically due on demand and there is a clear and distinct history of customers making consistent payments.

Total population

Payment accuracy revenue consists of revenue for our coordination of benefits and payment integrity services.
Population health management revenue is derived from contracts with health plans and other risk-bearing entities that can span years with the option to renew. Types of service contracts could include: (a) programs designed to improve member engagement; and (b) outreach services designed to improve clinical outcomes. Most of these types of service contracts contain multiple promises, all of which are not distinct within the context of the contract. Therefore, the promises represent a single, distinct performance obligation for the types of services we offer. Revenue derived from these services is largely based on consideration associated with prices per order/transfer and PMPM/PMPY fees. The Company believes the output method is a reasonable measure of progress for the satisfaction of our performance obligations, which are satisfied over time, as it provides a faithful depiction of (1) our performance toward complete satisfaction of the performance obligation under the contract and (2) the value transferred to the customer of the services performed under the contract. The Company has elected the right to invoice practical expedient for recognition of revenue related to its performance obligations when the amount we have the right to invoice the customer corresponds directly with the value to the customer. Additionally, certain total population management contracts have distinct performance obligations related to software license and implementation fees which have historically been recognized as revenue ratably over the life of the contract. Lastly, we have a limited number of fixed fee arrangements where revenue is recognized over time as performance obligations are satisfied within one to three years. Upon adoption of ASC 606, revenue for software licenses is recognized at the beginning of the license period when control is transferred as the license is installed and revenue for implementation fees is recognized when control is transferred over time as the implementation is being performed. As the performance obligation is deemed to have been satisfied and control transferred to our customers for software licenses and implementation fees on or before December 31, 2017, the Company recorded a decrease to deferred revenue and an increase to opening retained earnings of $1.1 million, net of tax, as of January 1, 2018 for the cumulative impact of adopting ASC 606. Generally, total population health management contract payment terms are stated within the contract and are due within an explicitly stated time period (e.g., 30, 45, 60 days) from the date of invoice. A portion of the payment received may relate to future performance obligations and will result in an increase to deferred revenue until the obligation has been met.

In connection with Coordination

The Company's accounts receivable balance is net of Benefitsestimated variable consideration of $18.8 million and certain Payment Integrity services, lockboxes and their associated bank accounts are setup to support recoveries and remittances. Generally, these bank accounts are for the benefit of the Company’s customers.  Customer cash held in Company bank accounts for the benefit of the customer was approximately $5.4$17.1 million as of March 31, 2019.  This amount is included in cash2020 and cash equivalents and other current liabilitiesDecember 31, 2019, respectively, related to revenue recognized based on the accompanying consolidated balance sheet.  

expected recoveries and/or savings.






15


The Company’s revenue disaggregated by market for the three months ended March 31, 20192020 and 20182019 was as follows (in thousands):

 Three Months EndedThree Months Ended
March 31,
  March 31, 2019   March 31, 2018 20202019
Commercial $76,259  $71,785 Commercial$88,750  $76,259  
State  61,742   54,620 State68,669  61,742  
Federal  9,952   15,020 Federal13,993  9,952  
Total $147,953  $141,425 Total$171,412  $147,953  

A portion of the Company’s services are deferred and revenue is recognized at a later time. Deferred revenue was approximately $6.5$6.4 million and $5.6$4.2 million as of March 31, 20192020 and December 31, 2018,2019, respectively, and is included in Accounts payable, accrued expenses and other liabilities in the Consolidated Balance Sheets. Approximately $1.4$1.0 million of the December 31, 20182019 balance was recognized in revenue during the quarterthree months ended March 31, 2019.

2020.

Contract modifications are routine in nature and often done to account for changes in the contract specifications or requirements. In most instances, contract modifications are for services that are not distinct, and, therefore, modifications are accounted for as part of the existing contract. The Company has elected to use the practical expedient to expense the incremental costs of obtaining a contract if the amortization period of the asset that the Company would have otherwise recognized is one year or less.

In connection with coordination of benefits and certain payment integrity services, lockboxes and their associated bank accounts are set up to support recoveries and remittances. Generally, these bank accounts are for the benefit of the Company’s customers. Customer cash held in Company bank accounts for the benefit of the customer was approximately $18.0 million and $21.9 million as of March 31, 2020 and December 31, 2019, respectively. This amount is included in cash and cash equivalents and other current liabilities on the accompanying Consolidated Balance Sheet.  
3. Acquisitions
(a)Accent

On December 23, 2019, HMS acquired West Claims Recovery Services, LLC (“Accent”), a payment accuracy and cost containment business, for aggregate consideration of cash in the amount of $158.6 million, which was funded through cash on hand. The purchase price is subject to certain post-closing purchase price adjustments and the initial purchase price allocation as of the date of acquisition was based on a preliminary valuation. Estimates and assumptions for which the Company is still obtaining or evaluating information are subject to change up to one year from the acquisition date as additional information becomes available and adjustments may require a change in the amounts allocated to goodwill during the periods in which the adjustments are determined. As of March 31, 2020, HMS has not finalized the determination of fair values allocated to various assets and liabilities, including, but not limited to: receivables; intangible assets; accounts payable and accrued liabilities; potential loss contracts; and goodwill.

16


The intangible assets are valued using various methods which require several judgments, including growth rates, discount rates, customer attrition rates, and expected levels of revenues, earnings, cash flows and tax rates. The intangible assets are amortized over their estimated useful lives on a straight-line basis. Goodwill was determined based on the difference between the purchase price and the fair values of the tangible and intangible assets acquired. Goodwill recognized from the acquisition was the result of synergies to be realized from future revenue growth. Goodwill is deductible for tax purposes, has an indefinite useful life and will be included in the Company’s annual impairment testing or between annual tests if an indicator of impairment exists.

The preliminary allocation of the purchase price to the fair value of the assets acquired and the liabilities assumed as of December 23, 2019, the effective date of the acquisition, was as follows (in thousands):

3.
Cash and cash equivalents$9,400 
Accounts Receivablereceivable10,736 
Prepaid expenses129 
Property and equipment2,878 
Intangible assets68,400 
Goodwill79,997 
Other assets489 
Accounts Receivable Allowancepayable and accrued liabilities(13,395)
Total purchase price$158,634 

The Company’s


As of the period ended March 31, 2020, the Company made refinements to the December 23, 2019 preliminary purchase price allocation as reported at December 31, 2019. These refinements resulted in an increase in accounts receivable net, consistedand a decrease to goodwill of approximately $1.5 million. Substantially all the receivables acquired are expected to be collectible.

The purchase price allocated to the intangible assets acquired was as follows (in thousands, except for useful life):

Useful Life
(in years)
Customer relationships12$67,000  
Trade name31,400  
Fair value of intangibles acquired$68,400  


We incurred $2.1 million of acquisition related costs related to the Accent acquisition for the year ended December 31, 2019. The costs include consulting, legal and transaction costs, and have been recorded in selling, general and administrative expenses.

The financial results of Accent's operations since the date of acquisition have been included in the Company’s consolidated financial statements. Accent contributed approximately $10.9 million in revenue to HMS results of operations for the three months ended March 31, 2020.



(b) VitreosHealth
On September 16, 2019, HMS acquired VitreosHealth, Inc. ("VitreosHealth"), a company that offers predictive and prescriptive health insights utilized by population risk models, for aggregate consideration of $36.6 million, which was funded with cash on hand. The purchase price was subject to certain post-closing purchase price adjustments and the initial purchase price allocation as of the following (in thousands):

   March 31,
2019
   December 31,
2018
 
Accounts receivable $218,832  $220,455 
Allowance  (14,037)  (13,683)
Accounts receivable, net $204,795  $206,772 

We record an accounts receivable allowancedate of acquisition was based on historical patternsa preliminary valuation.

The Company's allocation of billing adjustments, length of operatingconsideration exchanged to the net tangible and collection cycleintangible assets acquired and customer negotiations, behaviors and payment patterns. Changes in these estimates are recorded to revenueliabilities assumed in the periodacquisition is based on estimated fair values as of change.September 16, 2019. The Company allocated the purchase price, net of cash acquired, to the following significant assets: intellectual property subject to amortization of $6.0 million, and goodwill of $30.2 million which represents the excess purchase price over the net identifiable tangible and intangible assets. There were no additional material allocations to assets and liabilities. The intangible assets are valued using various methods which require several judgments, including growth rates, discount rates, expected levels of revenues, earnings, cash flows and tax rates. The intangible assets are amortized over their estimated useful lives on a straight-line basis and are not expected to be deductible for tax purposes. The goodwill recognized from the acquisition was a result of expected synergies to be realized from future revenue growth, is a summary of the activitynot expected to be deductible for tax purposes, has an indefinite useful life and will be included in the accounts receivable allowance (Company’s annual impairment testing.
The results of VitreosHealth's operations since the date of acquisition have been included in thousands):

   March 31,
 2019
   December 31,
 2018
 
Balance--beginning of period $13,683  $14,799 
Provision  5,411   20,453 
Charge-offs  (5,057)  (21,569)
Balance--end of period $14,037  $13,683 

the Company's consolidated financial statements and are not considered material.

4.Intangible Assets and Goodwill


4.  Intangible Assets, Goodwill and Other Assets
(a) Intangible Assets
Intangible assets consisted of the following (in thousands, except for weighted average amortization period):

  Gross Carrying Amount   Accumulated
Amortization
   Net Carrying Amount   Weighted Average Amortization Period in Years 
March 31, 2019                
Gross Carrying AmountAccumulated
Amortization
Net Carrying AmountWeighted Average Amortization Period in Years
March 31, 2020March 31, 2020
Customer relationships $68,290  $(17,588) $50,702   12.7 Customer relationships$125,423  $(14,172) $111,251  11.8
Trade namesTrade names1,400  (128) 1,272  2.7
Intellectual property  21,700   (7,638)  14,062   3.9 Intellectual property27,700  (12,053) 15,647  3.8
Trade names  136   (117)  19   0.4 
Restrictive covenants  133   (115)  18   0.4 
Total $90,259  $(25,458) $64,801     Total$154,523  $(26,353) $128,170  

   Gross Carrying Amount   Accumulated
Amortization
  Net Carrying Amount   Weighted Average Amortization Period in Years 
December 31, 2018                
Customer relationships $156,790  $(104,740) $52,050   12.8 
Intellectual property  21,700   (6,670)  15,030   4.1 
Trade names  16,246   (16,215)  31   0.7 
Restrictive covenants  263   (234)  29   0.7 
Total $194,999  $(127,859) $67,140     




Gross Carrying AmountAccumulated
Amortization
Net Carrying AmountWeighted Average Amortization Period in Years
December 31, 2019
Customer relationships$135,290  $(21,637) $113,653  12.1
Trade names1,536  (147) 1,389  3.0
Intellectual property27,700  (10,893) 16,807  3.7
Total$164,526  $(32,677) $131,849  
Amortization expense of intangible assets is expected to approximate the following (in thousands):

Year ending December 31, AmortizationYear ending December 31,Amortization
2019 (excluding the three months ended March 31, 2019) $6,856 
2020  7,664 
2020 (excluding the three months ended March 31, 2020)2020 (excluding the three months ended March 31, 2020)$11,016  
2021  7,197 202114,247  
2022  7,197 202214,197  
2023  4,822 202311,405  
2024202410,330  
Thereafter  31,065 Thereafter66,975  
Total $64,801 Total$128,170  

For the three months ended March 31, 20192020 and 2018,2019, amortization expense related to intangible assets was $3.7 million and $2.3 million, and $6.1 million, respectively.

There was no change

(b) Goodwill
As a result of the Accent acquisition, the changes in the carrying amount of goodwill were as follows (in thousands):
Balance at December 31, 2019$599,351 
Accent acquisition(1,548)
Balance at March 31, 2020$597,803 

(c) Other Assets
Included in Other assets are Level 1 equity investments with a cost basis of $7.4 million. As of March 31, 2020 and December 31, 2019, the fair value measurement of the equity instrument was $8.6 million and $7.9 million, respectively. There were 0 sales, settlements issuances or transfers related to this level 1 instrument.
The Company recorded net unrealized gains of $0.7 million for the three months ended March 31, 2020. There were 0 realized or unrealized gains in the three months ended March 31, 2019.


These gains are reflected as a component of Other income in the accompanying Consolidated Statements of Income.
5.Accounts Payable, Accrued Expenses and Other Liabilities

19



5.  Accounts Payable, Accrued Expenses and Other Liabilities
Accounts payable, accrued expenses and other liabilities consisted of the following (in thousands):

  March 31,
2019
   December 31,
2018
 
    March 31,
2020
December 31,
2019
Accounts payable, trade $12,325  $12,394 Accounts payable, trade$14,474  $12,246  
Accrued compensation and other  16,236   42,833 Accrued compensation and other19,533  36,827  
Accrued operating expenses  28,164   19,675 Accrued operating expenses40,704  42,045  
Current portion of lease liabilities  6,353   - Current portion of lease liabilities6,531  6,629  
Total accounts payable, accrued expenses and other liabilities $63,078  $74,902 Total accounts payable, accrued expenses and other liabilities$81,242  $97,747  


6.

Income Taxes


6.  Income Taxes
The Company’s effective tax rate decreasedincreased to (9.3%)25.7% for the three months ended March 31, 20192020 from 32.0%(9.3)% for the three months ended March 31, 2018.2019. The effective tax rate for the three months ended March 31, 20192020 includes immaterial discrete tax benefits related to net equity compensation deductions offset by interest on uncertain tax benefits.deductions. For the three months ended March 31, 2019,2020, the differences between the federal statutory rate and our effective tax rate are tax expense items related to state taxes, equity compensation impacts, unrecognized tax benefits, including interest, officer compensation deduction limits, research and development tax credits, and other permanent differences.

The Company has current period foreign income tax expense and includes global intangible low-taxed income as current period income tax expense, both of which are not material to the overall financial statements.

Included in Other liabilities on the Consolidated Balance Sheets, are the total amount of unrecognized tax benefits of approximately $5.0 million and $4.8 million, as of March 31, 2019 and December 31, 2018, respectively, (net of the federal benefit for state issues) of approximately $4.4 million and $4.2 million, as of March 31, 2020 and December 31, 2019, respectively, that, if recognized, would favorably affect the Company’s future effective tax rate. Also included in Other liabilities on the Consolidated Balance Sheets, are accrued liabilities for interest expense and penalties related to unrecognized tax benefits of $0.9$0.8 million and $0.7 million as of March 31, 20192020 and December 31, 2018,2019, respectively. HMS includes interest expense and penalties in the provision for income taxes in the unaudited Consolidated Statements of Income. The amount of interest expense (net of federal and state income tax benefits) and penalties in the unaudited Consolidated Statements of Income for the three months ended March 31, 2020 and 2019 and 2018 was $0.2$0.1 million and $0.2 million, respectively. The Company believes it is reasonably possible that the amount of unrecognized tax benefits may decrease by $1.8$1.6 million over the next twelve months, due to the expiration of the statute of limitations in federal and various state jurisdictions.

20


HMS files income tax returns with the U.S. Federal government and various state territory, and local jurisdictions.jurisdictions and will file income tax returns in certain foreign jurisdictions in future periods as a result of its acquisition of VitreosHealth. HMS is generally no longer subject to U.S. Federal income tax examinations for years before 2013.2016. HMS operates in a number of state, local and localforeign jurisdictions. Accordingly, HMS is subject to state, local and localforeign income tax examinations based on the various statutes of limitations in each jurisdiction.

7.Estimated Liability For Appeals

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") was enacted in response to the novel coronavirus (COVID-19) pandemic. The CARES Act includes numerous provisions relating to, among other things, refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, net operating loss amounts and carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. Due to the recent enactment of the CARES Act, the Company is currently analyzing the potential impacts of this legislation on its financial position and results of operations.


7. Liability For Appeals
Under the Company’s contracts with certain commercial health plan customers and its Medicare Recovery Audit Contractor (“RAC”) contractscontract with the Centers for Medicare & Medicaid Services (“CMS”) (included within the Company’s payment integrity services revenue), providers have the right to appeal HMS claim findings and to pursue additional appeals if the initial appeal is found in favor of HMS’s customer. The appeal process established under the Medicare RAC contracts with CMS includes five levels of appeals, and resolution of appeals can take substantial time to resolve. HMS records (a) an actual return obligation liability for findings which have been previously adjudicated in favor of providers and (b) an estimated return obligation liability based on the amount of revenue that is subject to appeals and which are probable of being adjudicated in favor of providers following their successful appeal. The Company’s estimate is based on the Company’s historical experience. To the extent the amount to be returned to providers following a successful appeal exceeds or is less than the amount recorded, revenue in the applicable period would be reduced or increased by such amount.


The following roll-forward summarizes the activity in Estimated Liability for Appeals (in thousands):

   Original
RAC contract
   RAC 4
contract
   Commercial contracts   Total 
Balance at December 31, 2018 $19,380  $20  $2,323  $21,723 
Provision  -   530   3,053   3,583 
Appeals found in providers favor  -   (15)  (1,248)  (1,263)
Balance at March 31, 2019 $19,380  $535  $4,128  $24,043 

The Company’s original Medicare RAC contract with CMS expired on January 31, 2018. As a result of the original contract expiration, the Company’s contractual obligation with respect to any appeals resolved in favor of providers subsequent to the expiration date have ceased and therefore the Company released its estimated return obligation liability and increased revenue by $8.4 million during the first quarter of 2018.

The Company continues to assess the remaining CMS liability for the original Medicare RAC contract to determine management’s best estimate of liability for any findings which have been previously adjudicated prior to the expiration of the contract. Any future changes or modifications to the Medicare RAC contracts or to the Company’s commercial customer contracts may require the Company to apply different assumptions that could materially affect both the Company’s revenue and estimated liability for appeals in future periods.

balance was approximately $3.9 million and $3.6 million as of March 31, 2020 and December 31, 2019, respectively.

8.Credit Agreement


8.  Credit Agreement
In May 2013, we entered into a credit agreement (as amended and restated, the "Credit Agreement") with certain lenders and Citibank, N.A. as administrative agent. The Credit Agreement originally provided for an initial $500 million five-year revolving credit facility maturing on May 3, 2018.
On December 19, 2017, the Company entered into an amendment to its Amended and Restatedthe Credit Agreement, as amended (the “Credit Agreement”) which, among other things, extended the maturity of its then existing $500 million revolving credit facility by five years to December 2022 (the “Amended"Amended Revolving Facility”Facility"). The.The availability of funds under the Amended Revolving Facility includes sublimits for (a) up to $50 million for the issuance of letters of credit and (b) up to $25 million for swingline loans. In addition, the Company may increase the commitments under the Amended Revolving Facility and/or add one or more incremental term loan facilities, provided that such incremental facilities do not exceed in the aggregate the sum of (i) the greater of $120 million and 100% of Consolidated EBITDA (as defined in the Credit Agreement) and (ii) an additional amount so long as our first lien leverage ratio (as defined in the Credit Agreement) on a pro forma basis is not greater than 3.00:1.00, subject to obtaining commitments from the lenders therefor and meeting certain other conditions.

As of March 31, 20192020 and December 31, 2018,2019, the outstanding principal balance due on the Amended Revolving Facility was $240.0$240 million. NoNaN principal payments were made against the Amended Revolving Facility during the three months ended March 31, 2019.

2020.

21


Borrowings under the Amended Revolving Facility bear interest at a rate equal to, at the Company’s election (except with respect to swingline borrowings, which will accrue interest based only at the base rate), either:

a base rate determined by reference to the greatest of (a) the prime or base commercial lending rate of the administrative agent as in effect on the relevant date, (b) the federal funds effective rate plus 0.50% and (c) the one-month London Interbank Offered Rate (or any successor rate determined in accordance with the Credit Agreement) (“LIBO Rate”) plus 1.00%, plus an interest margin ranging from 0.50% to 1.00% based on the Company’s consolidated leverage ratio for the applicable period; or

an adjusted LIBO Rate, equal to the LIBO Rate for the applicable interest period multiplied by the statutory reserve rate (equal to (x) one divided by (y) one minus the aggregate of the maximum reserve percentage (including any marginal, special, emergency or supplemental reserves) established by the Board of Governors of the Federal Reserve System of the United States), plus an interest margin ranging from 1.50% to 2.00% based on the Company’s consolidated leverage ratio for the applicable period.

a base rate determined by reference to the greatest of (a) the prime or base commercial lending rate of the administrative agent as in effect on the relevant date, (b) the federal funds effective rate plus 0.50% and (c) the one-month London Interbank Offered Rate (or any successor rate determined in accordance with the Credit Agreement) (“LIBO Rate”) plus 1.00%, plus an interest margin ranging from 0.50% to 1.00% based on the Company’s consolidated leverage ratio for the applicable period; or
an adjusted LIBO Rate, equal to the LIBO Rate for the applicable interest period multiplied by the statutory reserve rate (equal to (x) one divided by (y) one minus the aggregate of the maximum reserve percentage (including any marginal, special, emergency or supplemental reserves) established by the Board of Governors of the Federal Reserve System of the United States), plus an interest margin ranging from 1.50% to 2.00% based on the Company’s consolidated leverage ratio for the applicable period.
In addition to paying interest on the outstanding principal, the Company is required to pay unused commitment fees on the Amended Revolving Facility during the term of the Credit Agreement ranging from 0.375% to 0.250% per annum based on the Company’s consolidated leverage ratio and letter of credit fees equal to 0.125% per annum on the aggregate face amount of each letter of credit, as well as customary agency fees. As part of a contractual agreement with a customer, the Company has an outstanding irrevocable letter of credit for $6.5 million, which is issued against its revolving credit facilitythe Amended Revolving Facility and expires June 30, 2019.

2020.

The Amended Revolving Facility is secured, subject to certain customary carve-outs and exceptions, by a first priority lien and security interest in substantially all tangible and intangible assets of the Company and certain subsidiaries of the Company. The Amended Revolving Facility contains certain restrictive covenants, which affect, among other things, the ability of the Company and its subsidiaries to incur indebtedness, create liens, make investments, sell or otherwise dispose of assets, engage in mergers or consolidations with other entities, and pay dividends or repurchase stock. The Company is also required to comply, on a quarterly basis, with two financial covenants: (i) a minimum interest coverage ratio of 3:00:1:00, and (ii) a maximum consolidated leverage ratio of 4.75:1.00 through December 2019 and 4.25:1.00 from and after January 2020. The consolidated leverage ratio is subject to a step-up to 5.25:1.00 for four full consecutive fiscal quarters following a permitted acquisition or similar investment. As of March 31, 2019,2020, the Company was in compliance with all terms of the Credit Agreement.

Interest expense and the commitment fees on the unused portion of the Company’s revolving credit facilityAmended Revolving Facility were as follows (in thousands):

 Three Months Ended March 31,Three Months Ended
March 31,
  2019   2018 20202019
Interest expense $2,526  $2,070 Interest expense$1,925  $2,526  
Commitment fees  156   239 Commitment fees160  156  

As of March 31, 20192020 and December 31, 2018,2019, the unamortized balance of deferred origination fees and debt issuance costs was $2.1$1.6 million and $2.2$1.7 million, respectively. For the three month
22


periods ended March 31, 20192020 and 2018,2019, HMS amortized $0.1 million and $0.1 million, respectively, of interest expense related to the Company’s deferred origination fees and debt issue costs.

9.Earnings Per Share


9.  Earnings Per Share
The following table reconciles the basic to diluted weighted average common shares outstanding using the treasury stock method (in thousands, except per share amounts):

 Three Months Ended
March 31,
Three Months Ended
March 31,
  2019   2018 20202019
Net income $19,642  $6,391 Net income$12,682  $19,642  
        
Weighted average common shares outstanding-basic  85,853   83,933 Weighted average common shares outstanding-basic88,202  85,853  
Plus: net effect of dilutive stock options and restricted stock units  2,761   1,749 Plus: net effect of dilutive stock options and restricted stock units1,399  2,761  
Weighted average common shares outstanding-diluted  88,614   85,682 Weighted average common shares outstanding-diluted89,601  88,614  
Net income per common share-basic $0.23  $0.08 
Net income per common share-diluted $0.22  $0.07 
Net income per common share -- basicNet income per common share -- basic$0.14  $0.23  
Net income per common share -- dilutedNet income per common share -- diluted$0.14  $0.22  

For the three months ended March 31, 2020 and 2019, (i) 1,015,141 and 2018, 215,353 and 3,118,939 stock options, respectively, were not included in the diluted earnings per share calculation because the effect would have been anti-dilutive. For the three months ended March 31, 2019 and 2018,(ii) restricted stock units representing 120,5165,053 and 58,743120,516 shares of the Company's common stock, respectively, were not included in the diluted earnings per share calculation because the effect would have been anti-dilutive.


23

10.Stock-Based Compensation

(a)Stock-Based Compensation Expense




10.  Stock-Based Compensation
(a) Long-Term Incentive Award Plans
The Company grants stock options and restricted stock units to HMS employees and non-employee directors of the Company under the HMS Holdings Corp. 2019 Omnibus Incentive Plan (the “2019 Omnibus Plan”), as approved by the Company’s shareholders on May 22, 2019. The 2019 Omnibus Plan replaces and supersedes the HMS Holdings Corp. 2016 Omnibus Incentive Plan.
(b) Stock-Based Compensation Expense
Total stock-based compensation expense in the Company’s unaudited Consolidated Statements of Income related to the Company’s long-term incentive award plans was as follows (in thousands):

 Three Months Ended March 31,Three Months Ended
March 31,
 2019 201820202019
Cost of services-compensation $4,124  $2,563 Cost of services-compensation$3,849  $4,124  
Selling, general and administrative  6,855   6,931 Selling, general and administrative9,661  6,855  
Total $10,979  $9,494 Total$13,510  $10,979  

(b)Stock Options

Stock-based

(c) Stock Options
For the three months ended March 31, 2020 and 2019, stock-based compensation expense related to stock options was approximately $5.6 million and $4.8 million, and $4.0 million for the three months ended March 31, 2019 and 2018, respectively.

Presented below is a summary of stock option activity for the three months ended March 31, 20192020 (in thousands, except for weighted average exercise price and weighted average remaining contractual terms):

  Number of Options   Weighted
Average
Exercise
Price
   Weighted
Average-
Remaining
Contractual
Terms
   Aggregate-
Intrinsic
Value
 
Outstanding balance at December 31, 2018  4,402  $17.07         
Number of OptionsWeighted
Average
Exercise
Price
Weighted
Average-
Remaining
Contractual
Terms
Aggregate
Intrinsic
Value
Outstanding balance at December 31, 2019Outstanding balance at December 31, 20192,411  $23.43  
Granted  560   39.52         Granted1,028  27.34  
Exercised  (1,443)  16.03         Exercised(14) 8.97  
Forfeitures  (134)  18.99         Forfeitures—  —  
Expired  -   -         Expired—  —  
Outstanding balance at March 31, 2019  3,385  $21.19   6.85  $33,767 
Expected to vest at March 31, 2019  1,061  $27.50   9.14  $6,486 
Exercisable at March 31, 2019  1,899  $16.67   5.14  $24,582 
Outstanding balance at March 31, 2020Outstanding balance at March 31, 20203,425  $24.68  7.93$12,430  
Expected to vest at March 31, 2020Expected to vest at March 31, 20201,363  $28.72  9.34$1,267  
Exercisable at March 31, 2020Exercisable at March 31, 20201,613  $20.31  6.42$10,612  

24


During the three months ended March 31, 20192020 and 2018,2019, the Company issuedreceived proceeds of $0.1 million and $23.1 million, respectively, for the issuance of 13,561 and 1,443,685 and 9,043 shares respectively, of the Company’s common stock upon the exercise of outstanding stock options, and received proceeds of $23.1 million and $0.1 million, respectively. The total intrinsic value of stock options exercised during the three months ended March 31, 2020 and 2019 was $0.2 million and 2018 was $25.8 million, and $0.01 million respectively.

As of March 31, 2019,2020, there was approximately $8.4$7.9 million of total unrecognized compensation cost related to stock options outstanding, which is expected to be recognized over a weighted average period of 1.441.6 years.


The weighted-average grant date fair value per share of the stock options granted during the three months ended March 31, 2020 and 2019 was $8.91 and 2018 was $13.82, and $6.83, respectively. HMS estimated the fair value of each stock option grant on the date of grant using a Black-Scholes option pricing model and weighted–average assumptions set forth in the following table:

 Three Months Ended
March 31,
Three Months Ended
March 31,
  2019   2018  20202019
Expected dividend yield  0%  0%Expected dividend yield%%
Risk-free interest rate  2.5%  2.7%Risk-free interest rate1.2 %2.5 %
Expected volatility  40.9%  42.5%Expected volatility41.1 %40.9 %
Expected life (years)  6.4   6.0 Expected life (years)6.36.4

The total tax benefits recognized on stock-based compensation related to stock options for the three months ended March 31, 2020 and 2019 was $2.6 million and 2018 was $11.3 million, respectively. 
(d) Restricted Stock Units
For the three months ended March 31, 2020 and $2.1 million, respectively. 

(c)Restricted Stock Units

Stock-based2019, stock-based compensation expense related to restricted stock units was approximately $7.9 million and $6.1 million, and $5.5 million for the three months ended March 31, 2019 and 2018, respectively.

Presented below is a summary of restricted stock units activity for the three months ended March 31, 2019 2020 (in thousands, except for weighted average grant date fair value per unit):

  Number of
Units
  Weighted Average
Grant Date Fair
Value per Unit
 
Outstanding balance at December 31, 2018  1,488  $17.60 
Number of
Units
Weighted Average
Grant Date Fair
Value per Unit
Outstanding balance at December 31, 2019Outstanding balance at December 31, 20191,239  $21.37  
Granted  408   34.43 Granted693  23.78  
Vesting of restricted stock units, net of units withheld for taxes  (377)  16.88 Vesting of restricted stock units, net of units withheld for taxes(293) 22.67  
Units withheld for taxes  (193)  16.88 Units withheld for taxes(141) 22.67  
Forfeitures  (63)  17.58 Forfeitures(1) 24.36  
Outstanding balance at March 31, 2019  1,263  $25.43 
Outstanding balance at March 31, 2020Outstanding balance at March 31, 20201,497  $21.60  


As of March 31, 2019, 1,027,1862020, 1,224,176 restricted stock units remained unvested and there was approximately $16.7$18.3 million of unrecognized compensation cost related to restricted stock units, which is expected to be recognized over a weighted average vesting period of 1.431.6 years.

11.Leases

The Company determines if an arrangement is a lease at inception. Operating leases are reported on the Company’s consolidated balance sheet within operating lease ROU assets, operating lease liabilities



25


11. Commitments and accounts payable, accrued expenses and other liabilities. Finance leases are reported on the Company’s consolidated balance sheets within other assets, other liabilities and accounts payable, accrued expenses and other liabilities.

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of the Company’s leases do not provide an implicit rate, we use the Company’s incremental borrowing rate based on the information available at the lease’s commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For certain real estate and equipment leases, the Company has lease agreements with lease and non-lease components, which are generally accounted for as a single component.

Contingencies


The Company primarily leases real estate, information technology equipment and data centers on terms that expire on various dates through 2026, some of which include options to extend the lease for up to 10 years. We evaluate whether to include the option period in the calculation of the ROU asset and lease liability on a lease-by-lease basis.

As of March 31, 2019, all operating and finance leases that create significant rights and obligations for the Company have commenced.

The components of lease expense for the three months ended March 31, 2019 were as follows (in thousands):

   Three Months Ended March 31, 2019 
   
Operating lease cost $1,656 
     
Finance lease cost:    
Amortization of right-of-use assets $8 
Interest on lease liabilities $1 
Total finance lease cost $9 

Supplemental cash flow and other information related to leases for the three months ended March 31, 2019 were as follows (in thousands):

   Three Months Ended March 31, 2019 
   
Cash paid for amounts included in measurement of lease liabilities:    
Operating cash flows from operating leases $1,833 
Operating cash flows from finance leases $1 
Financing cash flows from finance leases $8 
Right-of-use assets obtained in exchange for new lease liabilities:    
Operating leases $219 
Finance leases $238 


Supplemental balance sheet information related to leases as of March 31, 2019 consisted of the following (in thousands):

   March 31, 2019 
Operating Leases    
Operating lease right-of-use assets $20,110 
     
Other current liabilities $6,247 
Operating lease liabilities $18,677 
Total operating lease liabilities $24,924 
     
Finance Leases    
Other Assets $334 
     
Other current liabilities $106 
Other long-term liabilities $229 
Total finance leases liabiities $335 

The weighted-average remaining lease term for operating and finance leases are 4.5 years and 3 years, respectively. Weighted-average discount rates amount to 5.7% and 5.0% for operating and finance leases, respectively.

Sublease income for the three months ended March 31, 2019 and 2018 was $0.5 million and $0.4 million, respectively. 

Maturities of lease liabilities were as follows (in thousands):

Year ended December 31,  Operating Leases   Finance Leases 
2019 (excluding the three months ended March 31, 2019) $5,575  $90 
2020  7,272   120 
2021  5,568   120 
2022  3,275   29 
2023  3,034   - 
Thereafter  3,560   - 
Total lease payments  28,284   359 
Less: Imputed interest  (3,360)  (24)
Total lease obligation $24,924  $335 

12.Commitments and Contingencies

In February 2018, the Company received a Civil Investigative Demand (“CID”) from the Texas Attorney General, purporting to investigate possible unspecified violations of the Texas Medicaid Fraud Prevention Act. In March 2018, the Company provided certain documents and information in response to the CID. HMS has not received any further requests for informationfrom the government in connection with this CID.

In September 2018, a former employee filed an action in the New York County Supreme Court entitled Christopher Frey v. Health Management Systems, Inc. alleging retaliation under New York law. The complaint seeks recovery of an unspecified amount of monetary damages, including back pay and other compensatory and equitable relief. The Company has moved to dismiss the complaint. OnIn May 2, 2019, the Court held a hearingheard oral arguments on the Company’sCompany's motion to dismiss. The motion remains pending before the Court. The Company continues to believe that this claim is without merit and intends to vigorously defend this matter.


From time to time, HMS may be subject to investigations, legal proceedings and other disputes arising in the ordinary course of the Company’s business, including but not limited to regulatory audits, billing and contractual disputes, employment-related matters and post-closing disputes related to acquisitions. Due to the Company’s contractual relationships, including those with federal and state government entities, HMS’s operations, billing and business practices are subject to scrutiny and audit by those entities and other multiple agencies and levels of government, as well as to frequent transitions and changes in the personnel responsible for oversight of the Company’s contractual performance. HMS may have contractual disputes with its customers arising from differing interpretations of contractual provisions that define the Company’s rights, obligations, scope of work or terms of payment, and with associated claims of liability for inaccurate or improper billing for reimbursement of contract fees, or for sanctions or damages for alleged performance deficiencies. Resolution of such disputes may involve litigation or may require that HMS accept some amount of loss or liability in order to avoid customer abrasion, negative marketplace perceptions and other disadvantageous results that could affect the Company’s business, financial condition, results of operations and cash flows.

HMS records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and estimable, HMS does not establish an accrued liability.

13.Subsequent Events


12.  Subsequent Events
In connection with the preparation of these unaudited Consolidated Financial Statements, an evaluation of subsequent events was performed through the date of filing and there were no events that have occurred that would require adjustments to the financial statements or disclosures.


26

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following Management’s Discussion and Analysis is intended to help the reader understand the results of operations and financial condition of HMS. You should read this discussion and analysis in conjunction with the other sections of this Form 10-Q, including the Cautionary Note Regarding Forward-Looking Statements appearing prior to Part I, the information in Part II, Item 1A and the unaudited Consolidated Financial Statements and accompanying Notes thereto included in Part I, Item 1. The historical results set forth in Items 1 and 2 of Part I of this Form 10-Q should not be taken as necessarily indicative of our future operations or financial results.


Business Overview

At HMS, provides a broad range of cost containmentour mission is to make healthcare work better for everyone. We deliver healthcare technology, analytics and engagement solutions to helpthat advance the healthcare payers and at-risk providerssystem by helping healthcare organizations reduce costs, improve health outcomes and enhance memberconsumer experiences. Using industry-leading technology, analyticsOur comprehensive solutions include a broad range of payment accuracy and engagementpopulation health management services that offer value throughout the healthcare continuum. Through our solutions, we deliver coordinationsave billions of benefits, payment integrity and total population management solutions through our operating subsidiaries to move the healthcare system forwarddollars annually for our customers. We arecustomers while helping consumers lead healthier lives. HMS is managed and operateoperates as one business segment with a single management team that reports to the Chief Executive Officer.

 

hmsy-20200331_g2.jpg
We serve state Medicaid programs, commercial health plans, federal government health agencies, government and private employers, CHIPs and other healthcare payers. We also serve as a subcontractor for certain business outsourcing and technology firms. As of March 31, 2019,2020, our customer base included the following:

over 40 state Medicaid programs;

approximately 325 health plans, including 23 of the top 25 health plans nationally (based on membership) in support of their multiple lines of business, including Medicaid managed care, Medicare Advantage and group and individual health;

over 160 private employers;

CMS, the Centers for Disease Control and Prevention, and the Department of Veterans Affairs; and

PBMs, third-party administrators and other risk-bearing entities, including independent practice associations, hospital systems, ACOs and specialty care organizations.

over 40 state Medicaid programs;
approximately 325 health plans, including 22 of the top 25 health plans nationally (based on membership) in support of their multiple lines of business, including Medicaid managed care, Medicare Advantage and group and individual health;
over 150 private employers;
CMS, VA and the Centers for Disease Control and Prevention; and
PBMs, third-party administrators and other risk-bearing entities, including independent practice associations, hospital systems, ACOs and specialty care organizations.
COVID-19 Impact
On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a pandemic, which has spread globally and throughout the United States. We have taken a number of precautionary and preemptive steps to protect the safety and well-being of our
27


employees while ensuring continuity of service to our clients, including, transitioning all of our employees to working remotely, suspending non-essential employee travel, canceling participation in industry events and in-person group meetings, promoting social distancing and enhanced cleaning and sanitization efforts across office locations, and implementing protocols to quarantine employees who may have been exposed to COVID-19, or show relevant symptoms. We also commenced preparedness plans at our facilities to maintain continuity of operations, which provide for flexible work arrangements, and we have moved to a remote working environment without any significant disruptions to our business or control processes. Our management team is actively monitoring the situation and in constant communication with our workforce as well as with our customers and vendors. While COVID-19 has not had a material adverse effect on our operations to date, the extent of the impact in the future, if any, will depend on future developments, which are highly uncertain and cannot be predicted. We are closely monitoring the impact of COVID-19 on all aspects of our business, and may take further actions as may be required by federal, state or local authorities, or that we determine are in the best interests of our employees, customers and partners. As the conditions surrounding COVID-19 continue to evolve rapidly, we will continue to actively manage our response in collaboration with customers, government officials and stakeholders, and assess any potential impacts to our financial position and operating results, as well as adverse developments in our business. For further information regarding the effect of COVID-19 on the Company, please see Part II, Item 1A. Risk Factors to this Form 10-Q, which is incorporated herein by reference.
Critical Accounting Policies and Estimates

Since the date of our 20182019 Form 10-K, there have been no material changes to our critical accounting policies other than with respect to leases as described in Notes 1 and 11 to the unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q. With respect topolicies. Information regarding our critical accounting policies other than those for leases, refer to the discussioncan be found in our 20182019 Form 10-K under “Critical Accounting Policies and Estimates” in Part II, Item 7 and “Business and Summary of Significant Accounting Policies” in Note 1 to the Consolidated Financial Statements under Part II, Item 8.

As of the date of the unaudited Consolidated Financial Statements presented in this Form 10-Q, there have been no material financial impacts on our operations resulting from the COVID-19 pandemic. However, the future effects of this pandemic on economic and market conditions is uncertain and increases the subjectivity that will be involved in evaluating our estimates and assumptions underlying our critical accounting policies. Any events and changes in circumstances arising after March 31, 2020, including those resulting from the impacts of COVID-19, will be reflected in management’s estimates for future periods.
RESULTS


As of and for the three months ended March 31, 20192020 and March 31, 2018

Revenue of $148.0 million increased $6.6 million, or 4.7% over the same quarter in 2018; and

Operating income of $19.7 million increased by $7.8 million as compared to operating income of $11.9 million in the same quarter of the prior year.
2019

Revenue of $171.4 million increased $23.4 million, or 15.9% over the same quarter in 2019; and

Operating income of $18.5 million decreased by $1.2 million as compared to operating income of $19.7 million in the same quarter of the prior year.






28


Comparison of Three Months Ended March 31, 20192020 to March 31, 2018

  Three Months Ended    
dollars in millions March 31, $ Change % Change
  2019 2018 2019 vs 2018
Revenue $148.0  $141.4  $6.6   4.7%
Cost of Services :                
Compensation  57.5   56.1   1.4   2.5 
Direct project and other operating costs  20.2   16.6   3.6   21.7 
Information technology  13.1   12.3   0.8   6.5 
Occupancy  4.1   4.4   (0.3)  (6.8)
Amortization of acquisition related software and intangible assets  4.1   8.1   (4.0)  (49.4)
Total Cost of Services  99.0   97.5   1.5   1.5 
Selling, general and administrative expenses  29.3   32.0   (2.7)  (8.4)
Total Operating Expenses  128.3   129.5   (1.2)  (0.9)
Operating income  19.7   11.9   7.8   65.5 
Interest expense  (2.8)  (2.6)  (0.2)  7.7 
Interest income  1.0   0.1   0.9   900.0 
Income before income taxes  17.9   9.4   8.5   90.4 
Income taxes  (1.7)  3.0   (4.7)  (156.7)
Net Income  19.6   6.4   13.2   206.3%

2019

Three Months Ended
dollars in millionsMarch 31,$ Change% Change
202020192020 vs 2019
Revenue$171.4  $148.0  $23.4  15.9 %
Cost of services:
Compensation67.5  57.5  10.0  17.4  
Direct project and other operating expenses24.9  20.2  4.7  23.3  
Information technology14.9  13.1  1.8  13.7  
Occupancy4.3  4.1  0.2  4.9  
Amortization of acquisition related software and intangible assets5.5  4.1  1.4  34.1  
Total cost of services117.1  99.0  18.1  18.3  
Selling, general and administrative expenses35.8  29.3  6.5  22.2  
Total operating expenses152.9  128.3  24.6  19.2  
Operating income18.5  19.7  (1.2) (6.1) 
Interest expense(2.3) (2.8) 0.5  (17.9) 
Interest income0.2  1.0  (0.8) (80.0) 
Other income0.7  —  0.7  100.0  
Income before income taxes17.1  17.9  (0.8) 4.5  
Income taxes4.4  (1.7) 6.1  (358.8) 
Net income$12.7  $19.6  $(6.9) (35.2)%

Revenue (in millions)

hmsy-20200331_g3.jpg
Three Months Ended March 31 – 20192020 vs. 2018

2019

During the three months ended March 31, 2019,2020, revenue was $148.0$171.4 million, an increase of $6.6$23.4 million or 4.7%15.9% compared to revenue of $141.4$148.0 million for the prior year quarter.

By solution, which consists of coordination of benefits and analytical services, and included in analytical services are our payment integrity and total population management solutions:

oCoordination of benefits revenue increased $14.2 million or 15.5% which was attributable to incremental services and yield increases provided to existing customers in our cost avoidance and post payment recovery business.  

29
oPayment integrity revenue decreased $11.0 million or 28.4% primarily due to a $7.4 million decrease in Medicare RAC revenue and a $3.6 million decrease related to timing of replaced edits and customer approvals for new edits.
oTotal population management revenue increased $3.4 million or 30.9% due to growth in the Eliza business.

By market:

oCommercial health plan market revenue increased $4.5 million or 6.3%, which was primarily attributable to growth in the Eliza business and incremental services and yield increases provided to existing customers in our cost avoidance business.

oFederal government market revenue decreased $5.0 million or 33.3% compared to the prior year quarter due to the $8.4 million Medicare RAC reserve release.

oState government market revenue grew by $7.1 million or 13.0%, which was attributable to expanded scopes and yield improvements.




By solution:
Coordination of benefits revenue increased $12.2 million or 11.5%, largely driven by Accent related revenue of $10.9 million.  
Payment integrity revenue increased $11.6 million or 41.8% primarily due to an increased volume of claims activity.

By market:
Commercial health plan market revenue increased $12.5 million or 16.4%, which was primarily attributable to Accent related revenue of $10.9 million.
Federal government market revenue increased $4.0 million or 40.6% compared to the prior year quarter primarily due to increased federal related claims processed.
State government market revenue increased by $6.9 million or 11.2%, which was attributable to expanded scopes and yield improvements.
Total Cost of Services (in millions)

hmsy-20200331_g4.jpg
Three Months Ended March 31 – 20192020 vs. 2018

2019

During the three months ended March 31, 2019,2020, total cost of services was $99.0$117.1 million, an increase of $1.5$18.1 million or 1.5%18.3% compared to $97.5$99.0 million for the prior year quarter.

Compensation expense increased by $1.4 million primarily due to a reduction in capitalized software related projects.  
Direct project and other operating costs increased by $3.6 million due to increased labor and services utilized to support revenue generating activities.
Amortization of acquisition related software and intangible assets decreased by $4.0 million due to certain intangible assets becoming fully amortized in prior periods.  



Compensation expense increased by $10.0 million primarily due to payroll related costs as a result of the VitreosHealth and Accent acquisitions in the third and fourth quarters of 2019.
Direct project and other operating costs increased by $4.7 million due to increased labor and professional fees utilized to support acquisition related activities and other initiatives.
Information technology expense increased by $1.8 million due to an increase in the amortization of capitalized software, and other computer and equipment related costs.
Amortization of acquisition related software and intangible assets increased by $1.4 million due to an increase in intangible assets following the acquisition of VitreosHealth and Accent in the third and fourth quarters of 2019.

30


Selling, General and Administrative expenses (in millions)

hmsy-20200331_g5.jpg


Three Months Ended March 31 – 20192020 vs. 2018

2019

During the three months ended March 31, 2019,2020, SG&A expense was $29.3$35.8 million, a decreasean increase of $2.7$6.5 million or 8.4%22.2% compared to $32.0$29.3 million for the prior year quarter.

Compensation expense in 2019 decreased by $2.0 million due to a reduction in payroll related costs, variable compensation and fringe benefits.     

In the first quarter of 2019, other operating expenses decreased by $0.8 million.


Compensation costs increased $4.1 million compared to the prior year quarter due to an increase in payroll related costs and stock compensation.
Professional and consulting fees increased $1.3 million compared to the prior year quarter, primarily related to the acquisition of Accent which occurred in the fourth quarter of 2019.
Income Taxes

Three Months Ended March 31 – 20192020 vs. 2018

2019

The Company’s effective tax rate decreasedincreased to (9.3%)25.7% for the three months ended March 31, 20192020 compared to 32.0%(9.3)% for the three months ended March 31, 2018.2019. The effective tax rate for the three months ended March 31, 2019 includes2020 included an immaterial amount of discrete tax benefits related to net equity compensation deductions offset by interest on uncertain tax benefits.deductions. Excluding the above mentioned immaterial discrete tax items, and net federal tax reform benefit, our normalized effective tax rate would approximate 27%25.7% for the three months ended March 31, 2019.2020. For the three months ended March 31, 2019,2020, the differences between the federal statutory rate and our effective tax rate are tax expense items related to state taxes, equity compensation impacts, unrecognized tax benefits, including interest, officer compensation deduction limits, research and development tax credits, and other permanent differences.

24

On March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic, which provides numerous tax provisions and other stimulus measures. Due to the recent enactment of this legislation, the Company continues to assess the potential impacts the CARES Act may have on its financial position and results of operations.


Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

31



Liquidity and Capital Resources

The following tables should be read in conjunction with the unaudited Consolidated Financial Statements and Notes thereto in Part I, Item 1 of this Form 10-Q.

Our cash and cash equivalents, working capital and available borrowings under our revolving credit facility (based upon the borrowing base and financial covenants in our Credit Agreement) were as follows (in thousands):

   March 31,
2019
   December 31,
2018
 
Cash and cash equivalents $219,857  $178,946 
Working capital $378,069  $328,684 
Available borrowings under credit facility $253,500  $253,500 

March 31, 2020December 31, 2019
Cash and cash equivalents$148,033  $139,268  
Working capital$321,105  $296,093  
Available borrowings under credit facility$253,500  $253,500  
The following is a summary of our cash flows (in thousands):

  Three Months Ended
March 31,
   2019   2018 
Net cash provided by operating activities $28,522  $14,737 
Net cash used in investing activities  (3,990)  (5,754)
Net cash provided by/(used in) financing activities  16,379   (8,398)
Net increase in cash and cash equivalents $40,911  $585 

Three Months Ended
March 31,
20202019
Net cash provided by operating activities$17,094  $28,522  
Net cash used in investing activities(5,017) (3,990) 
Net cash (used in)/provided by financing activities(3,312) 16,379  
Net increase in cash and cash equivalents$8,765  $40,911  
Our principal sourcesources of cash hashave been our cash flow from operations and our $500 million five-year revolving credit facility. Other sources of cash include proceeds from the exercise of stock options and tax benefits associated with stock option exercises. The primary uses of cash include, but are not limited to, acquisitions, strategic investments, capital investments, compensation expenses, data processing, direct project and other operating costs, SG&A expenses and other expenses.

We believe that expected cash flows from operations, available cash and cash equivalents, and funds available under our revolving credit facility will be sufficient to meet our liquidity requirements for the following year, which include:

the working capital requirements of our operations;

investments in our business;

business development activities; and

repurchases of common stock.

▪ the working capital requirements of our operations;
▪ investments in our business; and
▪ business development activities.
Any projections of future earnings and cash flows are subject to substantial uncertainty.uncertainty, particularly in light of the rapidly changing market and economic conditions created by the COVID-19 pandemic. We may need to access debt and equity markets in the future if unforeseen costs or opportunities arise, to meet working capital requirements, fund acquisitions or investments or repay our indebtedness under the Credit Agreement. If we need to obtain new debt or equity financing in the future, the terms and availability of such financing may be impacted by economic and financial market conditions as well as our financial condition and results of operations at the time we seek additional financing.

25

While we did not incur significant disruptions during the three months ended March 31, 2020 from COVID-19, we will continue to assess our liquidity needs and anticipated capital requirements as we move forward.

32



Cash Flows from Operating Activities

Net cash provided by operating activities for the three months ended March 31, 20192020 was $28.5$17.1 million, a $13.8$11.4 million increasedecrease compared to net cash provided by operating activities of $14.7$28.5 million for the three months ended March 31, 2018.2019. The increasedecrease was primarily related to an increasea $6.9 million decrease in net income of $13.2and a $7.9 million and increases in reconciling items of $9.9 million. These increases were offset by decreasesdecrease resulting from changes in operating assets and liabilities of approximately $9.3 million.

reconciling items.

Cash Flows from Investing Activities

Net cash used in investing activities for the three months ended March 31, 20192020 was $4.0$5.0 million, an $1.8a $1.0 million decreaseincrease compared to net cash used in investing activities of $5.8$4.0 million for the three months ended March 31, 2018.2019. The decreaseincrease was primarily relatedattributable to reductions in purchases of property and equipment and investment in capitalized software.

Cash Flows from Financing Activities

Net cash provided by/(used in)in financing activities for the three months ended March 31, 20192020 was $16.4$3.3 million, a $24.8$19.7 million increasedecrease compared to net cash used inprovided by financing activities of $8.4$16.4 million for the three months ended March 31, 2018.2019. The increasedecrease was primarily related to a $19.6 million decrease in proceeds from the exercise of stock options.

options, net of payments of tax withholdings.

Contractual Obligations

There have been no material changes outside the ordinary course of business in our contractual obligations as presented in our 20182019 Form 10-K.

Recently Issued Accounting Pronouncements

The information set forth under the caption “Recently Issued“Summary of Significant Accounting Pronouncements Not Yet Adopted”Policies” in Note 1 to the unaudited Consolidated Financial Statements in Part I, Item 1 is incorporated herein by reference.

Item 3.Quantitative and Qualitative Disclosures About Market Risk


Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes to the market risks discussed in Item 7A to Part II of our 20182019 Form 10-K.

Item 4.Controls and Procedures


Item 4. Controls and Procedures
We are responsible for maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management
33


is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) under the Exchange Act, management, with the participation of our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as of March 31, 2019.2020. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to provide reasonable assurance that their objectives were met as of the end of the period covered by this Form 10-Q.

There have been no changes in the Company's internal control over financial reporting identified in connection with the evaluation of our controls performed during the three months ended March 31, 2019,2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


34



PART II — OTHER INFORMATION

Item 1.Legal Proceedings


Item 1. Legal Proceedings
The information set forth under the caption “Commitments and Contingencies” in Note 1211 to the unaudited Consolidated Financial Statements of this Form 10-Q is incorporated herein by reference.

Item 1A.Risk Factors


Item 1A. Risk Factors
In addition to the information set forth in this Form 10-Q, the risks that are discussed in our 20182019 Form 10-K, under the headings “Business” of Part I, Item 1, “Risk Factors” of Part I, Item 1A, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of Part II, Item 7 and “Quantitative and Qualitative Disclosures About Market Risk” of Part II, Item 7A, should be carefully considered as such risks could materially affect the Company’s business, financial condition or future results. ThereOther than the risk factor set forth below, there has been no material change in the Company’s risk factors from those described in our 20182019 Form 10-K.

These

The risks that are discussed in our 2019 Form 10-K and the risk factor set forth below are not the only risks facing the Company. Additional risks and uncertainties not currently known to the Company or that it currently deems to be immaterial also may have a material adverse effect on the Company’s business, financial condition or future results.


The effects of the COVID-19 pandemic could disrupt our operations and adversely affect our business, financial condition, results of operations and cash flows.
Item 6.Exhibits

The widespread outbreak of COVID-19 has created significant volatility, uncertainty, and disruption in economic activity and financial markets globally. Although the outbreak of COVID-19 did not materially adversely impact our results of operations for the three months ended March 31, 2020 and has not had a material adverse effect on our operations to date, there can be no assurance that COVID-19 will not have a material adverse effect on our future operational and financial performance. The extent to which COVID-19 could impact our operational and financial performance in future periods is currently uncertain and will depend on numerous evolving factors and future developments that we may not be able to accurately predict and to which we may not be able to respond. Such factors and developments include, but are not limited to: the duration, severity and spread of the outbreak; actions taken by government authorities to contain and mitigate COVID-19 and the effectiveness of such actions; the effect on the U.S. and global economies and actions taken in response; the overall impact on the businesses of our customers, partners, vendors and suppliers; the health of and effect on our workforce; the future effects to our operational and financial results of the changes we have made to protect the safety and well-being of our employees and future operational disruptions or challenges we may face; increased cybersecurity and information security risk as a result of the transition of our employees to a remote work environment; and how quickly and to what extent normal economic and operating conditions may resume. Further, our management has been intensely focused on mitigating COVID-19, which has required and will continue to require, a large investment of time, attention and resources. Although we have yet to experience a significant disruption of our operations as a result of the COVID-19 pandemic, a prolonged outbreak could, among other things, strain our business continuity plans, create delays in our growth and strategic initiatives, reduce our sales and marketing activities, limit our access to financing on favorable terms, increase the Company’s exposure to potential impairment charges related to goodwill and intangible assets, hinder our ability to support our clients and operate our
35


business effectively, heighten the risk of disruption to our information and reporting systems and internal controls, including those over financial reporting and other risk management systems, or require us to incur substantial costs. We cannot predict the degree to which COVID-19 will ultimately impact our operations, however, the effects of the COVID-19 pandemic, alone or taken together, could adversely affect our future business, financial condition, results of operations and cash flows, and may also heighten other risks to which the Company is subject, including risks discussed in our 2019 Form 10-K.
36


Item 6. Exhibits
The exhibits may include agreements to which the Company is a party or has a beneficial interest. The agreements have been filed to provide investors with information regarding their respective terms. The agreements are not intended to provide any other actual information about the Company or its business or operations. In particular, the assertions embodied in any representations, warranties, and covenants contained in the agreements may be subject to qualifications with respect to knowledge and materiality different from those applicable to investors and may be qualified by information in disclosure schedules not included with the exhibits. These disclosure schedules may contain information that modifies, qualifies and creates exceptions to the representations, warranties and covenants set forth in the agreements. Moreover, certain representations, warranties, and covenants in the agreements may have been used for the purpose of allocating risk between parties, rather than establishing matters as facts. In addition, information concerning the subject matter of the representations, warranties and covenants may have changed after the date of the respective agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures. Accordingly, investors should not rely on the representations, warranties and covenants in the agreements as characterizations of the actual state of facts about the Company or its business or operations on the date hereof.

Where an exhibit is filed by incorporation by reference to a previously filed registration statement or report, such registration statement or report is identified after the description of the exhibit.

Exhibit

Number

Description
Exhibit
Number
Description
3.1
3.1
3.2
10.1Separation, Waiver and General Release Agreement, dated January 9, 2019, by and between Semone Neuman and HMS Holdings Corp. (incorporated by reference to Exhibit 10.9 to the Company’s Annual Report on Form 10-K (File No. 000-50194) as filed with the SEC on February 25, 2019)
31.1
31.1
31.2
32.1
32.2

28


37


101.INS
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document

_________________________

Indicates a management contract or compensatory plan, contract or arrangement
104*The certifications attached hereto asCover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 32.1 and Exhibit 32.2 are furnished with this Form 10-Q and shall not be deemed “filed” by the Company for purposes of Section 18 of the Exchange Act101)


* The certifications attached hereto as Exhibit 32.1 and Exhibit 32.2 are furnished with this Form 10-Q and shall not be deemed “filed” by the Company for purposes of Section 18 of the Exchange Act

38


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date:
Date:May 10, 201911, 2020HMS HOLDINGS CORP.
By:
By:/s/ William C. Lucia
William C. Lucia

President and Chief Executive Officer

(Principal Executive Officer)
By:
By:/s/ Jeffrey S. Sherman
Jeffrey S. Sherman

Executive Vice President, Chief Financial Officer and Treasurer

(Principal Financial Officer)

30


39